Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Modelling: Computing cancer.

Savage N.

Nature. 2012 Nov 22;491(7425):S62-3. No abstract available.

PMID:
23320290
2.

Antiangiogenic agents: fueling cancer's hypoxic roots.

Conley SJ, Wicha MS.

Cell Cycle. 2012 Apr 1;11(7):1265-6. doi: 10.4161/cc.19890. Epub 2012 Apr 1. No abstract available.

3.

Bevacizumab (Avastin).

Mukherji SK.

AJNR Am J Neuroradiol. 2010 Feb;31(2):235-6. doi: 10.3174/ajnr.A1987. Epub 2009 Dec 24. Review.

4.

Antiangiogenic therapy for cancer: an update.

Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR.

Pharmacotherapy. 2012 Dec;32(12):1095-111. doi: 10.1002/phar.1147. Review.

5.

Metabolic effects of anti-angiogenic therapy in tumors.

Zulato E, Curtarello M, Nardo G, Indraccolo S.

Biochimie. 2012 Apr;94(4):925-31. doi: 10.1016/j.biochi.2012.01.001. Epub 2012 Jan 11. Review.

PMID:
22245704
6.

[Anti-angiogenetic agents for solid tumors].

Blay JY.

Rev Med Interne. 2007 Jun;28 Suppl 1:S7-8. Epub 2007 Apr 20. French. No abstract available.

PMID:
17482319
7.

A new weapon for attacking tumor blood vessels.

Semenza GL.

N Engl J Med. 2008 May 8;358(19):2066-7. doi: 10.1056/NEJMcibr0800272. No abstract available.

PMID:
18463385
8.

[VEGF in neoplastic angiogenesis].

Chekhonin VP, Shein SA, Korchagina AA, Gurina OI.

Vestn Ross Akad Med Nauk. 2012;(2):23-33. Review. Russian.

PMID:
22642175
9.

A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy.

D'Onofrio A, Gandolfi A.

Math Med Biol. 2009 Mar;26(1):63-95. doi: 10.1093/imammb/dqn024. Epub 2008 Nov 25.

PMID:
19033598
10.

[Bevacizumab].

Taéron C.

Rev Infirm. 2009 Jan-Feb;(147):46-8. French. No abstract available.

PMID:
19317091
11.

Limiting supply.

[No authors listed]

Nat Rev Cancer. 2008 Aug;8(8):577. doi: 10.1038/nrc2461.

PMID:
18672479
12.

Angiogenesis inhibitors and the need for anti-angiogenic therapeutics.

Dass CR, Tran TM, Choong PF.

J Dent Res. 2007 Oct;86(10):927-36. Review.

PMID:
17890668
13.

Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data.

Titz B, Kozak KR, Jeraj R.

Phys Med Biol. 2012 Oct 7;57(19):6079-101. doi: 10.1088/0031-9155/57/19/6079. Epub 2012 Sep 13.

14.

The new cancer blockers.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2004 Oct;17(8):1-2, 7. No abstract available.

PMID:
15602777
15.

Targeting coagulation to the tumor microvasculature: perspectives and therapeutic implications from preclinical studies.

Narazaki M, Tosato G.

J Natl Cancer Inst. 2005 May 18;97(10):705-7. Review. No abstract available.

PMID:
15900035
16.

[Neoplastic angiogenesis].

Khosravi Shahi P, Castillo Rueda AD, Pérez Manga G.

An Med Interna. 2008 Jul;25(7):366-9. Review. Spanish.

17.

Computational modeling of tumor response to vascular-targeting therapies--part I: validation.

Gevertz JL.

Comput Math Methods Med. 2011;2011:830515. doi: 10.1155/2011/830515. Epub 2011 Mar 23.

18.

Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.

Magné N, Chargari C, Levy A, Guy JB, Merrouche Y, Spano JP.

J Chemother. 2014 Aug;26(4):253-5. doi: 10.1179/1973947813Y.0000000109. Epub 2013 Dec 6.

PMID:
24090564
19.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
20.

Cancer: The nuances of therapy.

Ellis LM, Reardon DA.

Nature. 2009 Mar 19;458(7236):290-2. doi: 10.1038/458290a. No abstract available.

PMID:
19295595

Supplemental Content

Support Center